Clesrovimab: Clinical Trials

3 trials of Clesrovimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 11Completed 1
Phase 31Completed 1

Follow Clesrovimab: new trials by email Literature Review of Clesrovimab trials Research Report on Clesrovimab

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Clesrovimab, Placebo - Respiratory Syncytial Virus Infection
Phase 2 / Phase 3CompletedMerck Sharp & Dohme LLC36322021-04-072026-02-11
Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005)
Clesrovimab, Placebo, RSV-A Memphis 37b - Respiratory Syncytial Viruses
Phase 2CompletedMerck Sharp & Dohme LLC802019-10-282022-09-14
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
Clesrovimab, Placebo - Respiratory Tract Infection, Respiratory Syncytial Virus
Phase 1 / Phase 2CompletedMerck Sharp & Dohme LLC1832018-09-202025-01-14

Conditions studied

Respiratory Syncytial Virus Infections (1)  ·  Respiratory Tract Infections (1)

Sponsors

Merck Sharp & Dohme LLC (3)

Countries

Chile (2)  ·  Colombia (2)  ·  South Africa (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Israel (1)  ·  Italy (1)

Results publications

PMID 34774184, PMID 34775220, PMID 39590882, PMID 39601265, PMID 40673795, PMID 40961446

NIH funding

2017 (1), 2018 (1)